Valuation: Harvard Bioscience, Inc.

Market Cap 37.97M 33.79M 31.32M 28.38M 53.34M 3.6B 54.23M 376M 148M 1.88B 142M 139M 6B P/E 2026 *
-4.29x
P/E 2027 * -17.9x
Enterprise Value 37.97M 33.79M 31.32M 28.38M 53.34M 3.6B 54.23M 376M 148M 1.88B 142M 139M 6B EV / Sales 2026 *
0.42x
EV / Sales 2027 * 0.4x
Free-Float
90.61%
Yield 2026 *
-
Yield 2027 * -
1 day+3.09%
1 week+0.85%
Current month+5.30%
1 month+4.91%
3 months+36.50%
6 months+19.31%
Current year+24.70%
1 week 7.9
Extreme 7.9
8.4
1 month 7.85
Extreme 7.85
8.8
Current year 4
Extreme 4
8.8
1 year 3.95
Extreme 3.95
9.4
3 years 2.81
Extreme 2.813
55.6
5 years 2.81
Extreme 2.813
82.3
10 years 2.81
Extreme 2.813
87.5
Manager TitleAgeSince
Chief Executive Officer 55 2025-07-27
Director of Finance/CFO 63 2025-05-11
Chief Tech/Sci/R&D Officer - 2019-03-31
Director TitleAgeSince
Director/Board Member 52 2017-10-23
Director/Board Member 55 2025-06-01
Director/Board Member 52 2025-07-15
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26 Free

Chief Executive Officer

75,000 0.1677%
3/20/26 Free

Chief Financial Officer

30,000 0.0671%
3/17/26 Buy

Director

10,000 0.0224%
Change 5-day change 1-year change 3-year change Capi.($)
+3.09%+0.85%+109.55%-80.51% 37.97M
+1.18%+3.67%+26.39%+48.03% 254B
-0.08%+0.63%+7.61%+8.94% 158B
+1.11%+3.78%-4.46%+64.10% 155B
+1.18%+5.24%-54.66%-8.93% 66.06B
+0.59%+5.65%+11.46%+59.02% 51.6B
-1.27%+2.42%-15.56%-12.63% 51.82B
+1.23%+3.54%+17.27%+27.07% 50.89B
+1.83%+0.82%+20.99%+58.39% 48.78B
+1.97%+3.18%+29.04%+74.59% 43.51B
Average +0.36%+2.64%+14.76%+23.81% 87.92B
Weighted average by Cap. -0.45%+2.40%+7.46%+37.31%

Financials

2026 *2027 *
Net sales 89.8M 79.93M 74.08M 67.13M 126M 8.51B 128M 889M 349M 4.45B 337M 330M 14.2B 94.55M 84.16M 78M 70.68M 133M 8.96B 135M 936M 368M 4.69B 355M 347M 14.95B
Net income -8.9M -7.92M -7.34M -6.65M -12.5M -843M -12.71M -88.1M -34.61M -441M -33.38M -32.69M -1.41B -2.2M -1.96M -1.81M -1.64M -3.09M -208M -3.14M -21.78M -8.55M -109M -8.25M -8.08M -348M
Net Debt - -
Projected Income Statement - Annual - Harvard Bioscience, Inc.
Logo Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Employees
328
Date Price Change Volume
26-10-20 US$8.340 +3.09% 23,423
26-10-19 US$8.090 0.00% 12,593
26-10-16 US$8.090 -2.65% 20,181
26-10-15 US$8.310 +1.96% 16,561
26-10-14 US$8.150 -1.45% 11,623
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Harvard Bioscience, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.340USD
Average target price
7.500USD
Spread / Average Target
-10.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Harvard Bioscience, Inc.
  1. Stock Market
  2. Stocks
  3. HBIO Stock